MEXCORT 12

Description

MEXCORT 12 contains Deflazacort 12 mg, a systemic corticosteroid used under medical supervision when glucocorticoid therapy is appropriate. Deflazacort has anti-inflammatory and immunosuppressive properties. Therefore, healthcare professionals may use it as part of treatment for selected inflammatory, allergic, autoimmune or other steroid-responsive conditions, depending on the patient’s diagnosis and treatment plan.

For related Deflazacort formulations, MEXCORT-6 can be referred to for additional product information on Deflazacort 6 mg Tablets.

Therapeutic Segment

Corticosteroids | Anti-inflammatory | Immunosuppressive Therapy

Uses of MEXCORT 12

Doctors may prescribe MEXCORT 12 when systemic corticosteroid treatment is appropriate for a particular medical condition. Depending on the clinical situation, deflazacort may form part of treatment for:

• Selected inflammatory conditions
• Certain allergic conditions
• Autoimmune disorders
• Other conditions that respond to systemic corticosteroid therapy

In addition, deflazacort has a specific approved indication for Duchenne muscular dystrophy in certain patients in current U.S. labeling. However, the exact indication, dose and treatment duration depend on the patient’s condition and the applicable prescribing information.

MEXCORT 12 should therefore be used only according to the advice of a qualified healthcare professional.

Key Benefits of Deflazacort 12 mg

• Contains Deflazacort 12 mg.
• Belongs to the glucocorticoid class of corticosteroids.
• Provides anti-inflammatory and immunosuppressive activity.
• Comes in an oral tablet dosage form.
• Supplied in 10 × 10 ALU-ALU packaging.

Moreover, healthcare professionals can adjust corticosteroid treatment according to the patient’s response, condition and duration of therapy.

How MEXCORT 12 Works

Deflazacort is a glucocorticoid that acts through glucocorticoid receptors after conversion to its active metabolite. It influences the expression of proteins involved in inflammatory and immune responses. As a result, it can reduce inflammation and modify excessive immune activity.

Common Side Effects of Deflazacort

Side effects can vary with the dose and duration of treatment. Some patients may experience:

• Increased appetite
• Weight gain
• Cushingoid changes
• Increased blood glucose
• Increased blood pressure
• Mood or sleep changes
• Increased susceptibility to infections
• Stomach discomfort

With prolonged treatment, corticosteroids can also affect bone health, eye health and adrenal function. Therefore, patients receiving longer-term therapy may require appropriate medical monitoring.

Important Safety Information

Use MEXCORT 12 only under the direction of a qualified healthcare professional.

• Deflazacort can suppress immune responses. Therefore, it may increase the risk of infections or make existing infections more difficult to control.
• Tell your doctor if you currently have an infection or have recently been exposed to an infectious illness.
• Corticosteroids can increase blood glucose levels. Patients with diabetes may therefore need closer monitoring.
• Deflazacort can affect blood pressure, fluid balance and potassium levels, particularly during prolonged treatment.
• Long-term corticosteroid therapy can reduce bone mineral density and increase the risk of osteoporosis.
• Corticosteroids can affect the eyes and may contribute to cataracts, glaucoma or certain eye infections.
• Mood and behavioural changes can occur during corticosteroid treatment. Report significant changes in mood, sleep or behaviour to your healthcare professional.
• Do not stop prolonged corticosteroid treatment suddenly. Your doctor may gradually reduce the dose to help prevent withdrawal and adrenal insufficiency.
• Tell your doctor about all prescription medicines, over-the-counter medicines and supplements you take.
• Certain medicines can alter deflazacort exposure. For example, moderate or strong CYP3A4 inhibitors can require dosage adjustment, while CYP3A4 inducers may reduce its effectiveness.
• Live or live-attenuated vaccines require special consideration during immunosuppressive corticosteroid therapy.
• Seek medical attention for severe allergic reactions, serious infections, significant vision changes or other concerning symptoms.

For detailed prescribing information and safety warnings, refer to the DailyMed Deflazacort Drug Label.

Dosage & Administration

The appropriate deflazacort dose depends on the condition being treated, the patient’s age, response to therapy and other clinical factors. Therefore, take MEXCORT 12 exactly as prescribed by the healthcare professional.

For specific approved uses, current prescribing information uses weight-based dosing rather than one fixed dose for every patient. Consequently, the 12 mg tablet strength may form part of an individualized treatment regimen.

Take the tablet as directed by your doctor. Deflazacort tablets can generally be taken with or without food. However, follow the instructions provided with your prescription.

Most importantly, do not increase the dose, reduce it or stop treatment on your own. When systemic corticosteroid treatment continues beyond a few days, the healthcare professional may need to reduce the dose gradually.

Storage

Store MEXCORT 12 in a cool, dry place away from direct sunlight and moisture. Keep the tablets in their original packaging. Also, keep the medicine out of the reach of children.